ONCOmmunity

Effectiveness and feasibility of selective intra-arterial low dose of cisplatin infusion and concomitant radiotherapy for patients with advanced laryngeal cancer with impaired renal function: A retrospective cohort study.

By: Yuji Imahara, Takeharu Ono, Norimitsu Tanaka, Shun-Ichi Chitose, Fumihiko Sato, Shuichi Tanoue, Takashi Kurita, Yusaku Miyata, Koichiro Muraki, Etsuyo Ogo, Chikayuki Hattori, Toshi Abe, Hirohito Umeno

Department of Otolaryngology - Head and Neck Surgery, Kurume University School of Medicine, Kurume, Japan.
2024-5-1; doi: 10.1002/hed.27873

Abstract

Background

Chemoradiation therapy with high-dose cisplatin is the standard regimen against advanced squamous cell carcinoma of the larynx (SCC-L). However, patients with renal dysfunction are ineligible for this regimen. We investigated the effectiveness and feasibility of selective intra-arterial low-dose cisplatin infusion and radiotherapy (modified [m]-RADPLAT) for patients with impaired renal function.

Methods

We retrospectively reviewed the data of 77 patients with SCC-L who received m-RADPLAT.

Results

Fourteen and 63 patients had creatinine clearance (CrCl) values of 30 ≤ CrCl < 60 mL/min and ≥60 mL/min, respectively. The m-RADPLAT regimen led to no significant changes in serum creatinine or CrCl values post-treatment. The 5-year local control, overall survival, and laryngectomy-free survival rates of the CrCl < 60 and ≥60 groups were 90.0% and 90.5%, 100% and 81.8%, and 100% and 79.0%, respectively. Grade 3 or higher toxicity rates were not significantly different between the groups.

Conclusions

The m-RADPLAT regimen yielded favorable survival rates and clinical outcomes in patients with impaired renal function.